26 Chapter 2 Variable Number of studies Pooled prevalence Beta-blockers 53 73.4 (66.8- 79.1) ACE inhibitors 44 55.8 (49.7 – 61.8) Aspirin 44 85.1 (79.7 – 89.3) Aspirin, clopidogrel or antiplatelet drugs 51 84.6 (79.6 – 88.5) Statins 50 78.9 (71.2 – 84.9) Insulin 9 11.6 (7.0 – 18.8) Antihypertensives (without specification) 8 46.5 (33.7 – 59.8) Diuretics 8 30.1 (24.3 – 36.6) Calcium chanel blockers 6 34.0 (19.4- 52.5) Nitrates 6 36.7 (24.1 – 51.5) Antiplatelet (without specification) 14 75.1 (55.5 – 87.9) Clopidogrel 13 50.0 (22.9 – 78.1) Dual antiplatelet therapy 3 80.0 (55.3 – 92.8) Lipid-lowering drugs 2 34.4 (9,1 – 73.4) Fibrates 2 73.1 (69.5 – 76.5) Note: Pooled prevalence results are expressed in percentage and 95% confidence interval. Table 2. Summary of the meta-analysis results. Time trends The prevalence of beta-blockers, ACEI/ARBs and statins use significantly increased with time. The use of all antiplatelet drugs and aspirin in particular remained relatively stable over time and the association between medication use and year of the study was not significant (Fig 6). The changes in use for other classes of medications were not significant, and they are shown in Supplementary Figure 6. There were too few observations in the lipid-lowering drugs (without specification) and fibrates to analyse time-trends.
RkJQdWJsaXNoZXIy MTk4NDMw